|
US4203990A
(en)
|
1979-04-30 |
1980-05-20 |
G. D. Searle & Co. |
Anti-diarrheal 2-substituted quinuclidines
|
|
DE58906678D1
(de)
|
1988-07-28 |
1994-02-24 |
Ciba Geigy |
Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung.
|
|
US4922901A
(en)
|
1988-09-08 |
1990-05-08 |
R. J. Reynolds Tobacco Company |
Drug delivery articles utilizing electrical energy
|
|
EP0402056A3
(en)
|
1989-06-06 |
1991-09-04 |
Beecham Group p.l.c. |
Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
|
|
CA2022886A1
(en)
|
1989-08-08 |
1991-02-09 |
Raymond Baker |
Substituted pyridines, their preparation, formulations and use in dementia
|
|
IN173570B
(enExample)
|
1989-11-23 |
1994-06-04 |
Pfizer |
|
|
DK40890D0
(da)
|
1990-02-16 |
1990-02-16 |
Ferrosan As |
Substituerede urinstofforbindelser, deres fremstilling og anvendelse
|
|
EP0492903A1
(en)
|
1990-12-21 |
1992-07-01 |
MERCK SHARP & DOHME LTD. |
Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
|
|
ATE198830T1
(de)
|
1991-03-01 |
2001-02-15 |
Univ Florida |
Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
|
|
US5212188A
(en)
|
1992-03-02 |
1993-05-18 |
R. J. Reynolds Tabacco Company |
Method for treatment of neurodegenerative diseases
|
|
US5276043A
(en)
|
1992-04-10 |
1994-01-04 |
R. J. Reynolds Tobacco Company |
Method for treatment of neurodegenerative diseases
|
|
US5977144A
(en)
*
|
1992-08-31 |
1999-11-02 |
University Of Florida |
Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
|
|
JP3034953B2
(ja)
|
1992-08-31 |
2000-04-17 |
ユニバーシティー オブ フロリダ リサーチ ファンデーション，インコーポレーテッド |
神経系の変性疾患の治療に有用なアナバセイン誘導体
|
|
IL107184A
(en)
|
1992-10-09 |
1997-08-14 |
Abbott Lab |
Heterocyclic ether compounds that enhance cognitive function
|
|
US5852041A
(en)
|
1993-04-07 |
1998-12-22 |
Sibia Neurosciences, Inc. |
Substituted pyridines useful as modulators of acethylcholine receptors
|
|
IL109451A0
(en)
*
|
1993-04-29 |
1994-07-31 |
Zeneca Ltd |
Heterocyclic derivatives
|
|
WO1995003306A1
(en)
|
1993-07-22 |
1995-02-02 |
E.I. Du Pont De Nemours And Company |
Arthropodicidal azacyclic heterocycles
|
|
US5493026A
(en)
|
1993-10-25 |
1996-02-20 |
Organix, Inc. |
Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
|
|
US5510355A
(en)
|
1994-09-06 |
1996-04-23 |
Bencherif; Merouane |
Depolarizing skeletal muscle relaxants
|
|
US5998404A
(en)
|
1994-10-24 |
1999-12-07 |
Eli Lilly And Company |
Heterocyclic compounds and their use
|
|
US5604231A
(en)
|
1995-01-06 |
1997-02-18 |
Smith; Carr J. |
Pharmaceutical compositions for prevention and treatment of ulcerative colitis
|
|
US5616707A
(en)
|
1995-01-06 |
1997-04-01 |
Crooks; Peter A. |
Compounds which are useful for prevention and treatment of central nervous system disorders
|
|
US5597919A
(en)
|
1995-01-06 |
1997-01-28 |
Dull; Gary M. |
Pyrimidinyl or Pyridinyl alkenyl amine compounds
|
|
US5824692A
(en)
|
1995-01-06 |
1998-10-20 |
Lippiello; Patrick Michael |
Pharmaceutical compositions for prevention and treatment of central nervous system disorders
|
|
US5859004A
(en)
|
1995-02-17 |
1999-01-12 |
Novo Nordisk A/S |
Use of heterocyclic compounds for the treatment of conditions caused by malfunctioning of the nicotinic cholinergic system
|
|
US5585388A
(en)
|
1995-04-07 |
1996-12-17 |
Sibia Neurosciences, Inc. |
Substituted pyridines useful as modulators of acetylcholine receptors
|
|
US5583140A
(en)
|
1995-05-17 |
1996-12-10 |
Bencherif; Merouane |
Pharmaceutical compositions for the treatment of central nervous system disorders
|
|
IL118279A
(en)
|
1995-06-07 |
2006-10-05 |
Abbott Lab |
Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
|
|
WO1997001556A1
(en)
|
1995-06-29 |
1997-01-16 |
Novo Nordisk A/S |
Novel substituted azacyclic or azabicyclic compounds
|
|
EP0853621A1
(en)
|
1995-09-22 |
1998-07-22 |
Novo Nordisk A/S |
Novel substituted azacyclic or azabicyclic compounds
|
|
US5712270A
(en)
|
1995-11-06 |
1998-01-27 |
American Home Products Corporation |
2-arylamidothiazole derivatives with CNS activity
|
|
US5616716A
(en)
|
1996-01-06 |
1997-04-01 |
Dull; Gary M. |
(3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
|
|
SE9600683D0
(sv)
|
1996-02-23 |
1996-02-23 |
Astra Ab |
Azabicyclic esters of carbamic acids useful in therapy
|
|
US5663356A
(en)
|
1996-04-23 |
1997-09-02 |
Ruecroft; Graham |
Method for preparation of aryl substituted alefinic secondary amino compounds
|
|
US5726189A
(en)
|
1996-05-03 |
1998-03-10 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
|
|
ZA9711092B
(en)
|
1996-12-11 |
1999-07-22 |
Smithkline Beecham Corp |
Novel compounds.
|
|
US5811442A
(en)
|
1997-02-21 |
1998-09-22 |
Bencherif; Merouane |
Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
|
|
US5861423A
(en)
|
1997-02-21 |
1999-01-19 |
Caldwell; William Scott |
Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
|
|
CA2289574C
(en)
|
1997-05-30 |
2007-04-24 |
Neurosearch A/S |
8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
|
|
AR013184A1
(es)
*
|
1997-07-18 |
2000-12-13 |
Astrazeneca Ab |
Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
|
|
US5952339A
(en)
|
1998-04-02 |
1999-09-14 |
Bencherif; Merouane |
Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
|
|
MXPA00009634A
(es)
|
1998-04-02 |
2005-06-20 |
Targacept Inc |
Derivados de azatriciclo[3.3.1.1]decano y composiciones farmaceuticas que los contienen.
|
|
AU765142B2
(en)
|
1998-06-01 |
2003-09-11 |
Ortho-Mcneil Pharmaceutical, Inc. |
Method for treating neurodegenerative disorders
|
|
US6310043B1
(en)
|
1998-08-07 |
2001-10-30 |
Governors Of The University Of Alberta |
Treatment of bacterial infections
|
|
GB9821503D0
(en)
|
1998-10-02 |
1998-11-25 |
Novartis Ag |
Organic compounds
|
|
US6953855B2
(en)
|
1998-12-11 |
2005-10-11 |
Targacept, Inc. |
3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
|
|
US6432975B1
(en)
|
1998-12-11 |
2002-08-13 |
Targacept, Inc. |
Pharmaceutical compositions and methods for use
|
|
US6734215B2
(en)
|
1998-12-16 |
2004-05-11 |
University Of South Florida |
Exo-S-mecamylamine formulation and use in treatment
|
|
SE9900100D0
(sv)
*
|
1999-01-15 |
1999-01-15 |
Astra Ab |
New compounds
|
|
FR2791678B1
(fr)
*
|
1999-03-30 |
2001-05-04 |
Synthelabo |
Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
|
|
SE9904176D0
(sv)
|
1999-11-18 |
1999-11-18 |
Astra Ab |
New use
|
|
SE0000540D0
(sv)
|
2000-02-18 |
2000-02-18 |
Astrazeneca Ab |
New compounds
|
|
GB0010955D0
(en)
|
2000-05-05 |
2000-06-28 |
Novartis Ag |
Organic compounds
|
|
IL153707A0
(en)
|
2000-06-27 |
2003-07-06 |
S A L V A T Lab Sa |
Carbamates derived from arylalkylamines
|
|
AU2001284645A1
(en)
|
2000-08-18 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
US6486172B2
(en)
|
2000-08-18 |
2002-11-26 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl compounds for treatment of disease
|
|
EP1381603A2
(en)
|
2000-08-18 |
2004-01-21 |
PHARMACIA & UPJOHN COMPANY |
Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
|
|
EP1311505A2
(en)
|
2000-08-21 |
2003-05-21 |
PHARMACIA & UPJOHN COMPANY |
Quinuclidine-substituted heteroaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
|
|
WO2002015662A2
(en)
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
|
|
AU2001282875A1
(en)
|
2000-08-21 |
2002-03-04 |
Pharmacia And Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
PE20020719A1
(es)
|
2000-12-22 |
2002-10-11 |
Almirall Prodesfarma Ag |
Derivados de carbamato de quinuclidina como agentes antimuscarinicos m3
|
|
US20020086871A1
(en)
*
|
2000-12-29 |
2002-07-04 |
O'neill Brian Thomas |
Pharmaceutical composition for the treatment of CNS and other disorders
|
|
US6569865B2
(en)
|
2001-06-01 |
2003-05-27 |
Astrazeneca Ab |
Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
|
|
EP1397366B1
(en)
|
2001-06-01 |
2007-02-07 |
AstraZeneca AB |
Novel ligand for nicotinic acetylcholine receptors useful in therapy
|
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
|
WO2003011837A1
(en)
|
2001-08-01 |
2003-02-13 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
WO2003018585A1
(en)
|
2001-08-24 |
2003-03-06 |
Pharmacia & Upjohn Company |
Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
|
|
JP2005504059A
(ja)
|
2001-08-24 |
2005-02-10 |
ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー |
疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン
|
|
DE60218493D1
(de)
|
2001-09-12 |
2007-04-12 |
Pharmacia & Upjohn Co Llc |
Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
|
|
US6858613B2
(en)
|
2002-02-19 |
2005-02-22 |
Pfizer Inc. |
Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
|
|
JP2005525357A
(ja)
|
2002-02-20 |
2005-08-25 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
α７ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物
|
|
KR20040099446A
(ko)
|
2002-04-18 |
2004-11-26 |
아스트라제네카 아베 |
헤테로시클릭 화합물
|
|
ATE484508T1
(de)
|
2002-04-18 |
2010-10-15 |
Astrazeneca Ab |
Furylverbindungen
|
|
ATE477256T1
(de)
*
|
2002-04-18 |
2010-08-15 |
Astrazeneca Ab |
Thienylverbindungen
|
|
AU2003253686A1
(en)
|
2002-08-01 |
2004-02-23 |
Pharmacia & Upjohn Company Llc |
1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
|
|
SE0202430D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
New Compounds
|
|
MXPA05001702A
(es)
|
2002-08-14 |
2005-04-19 |
Neurosearch As |
Derivados de quinuclidina novedosos y su uso.
|
|
SE0202465D0
(sv)
|
2002-08-14 |
2002-08-14 |
Astrazeneca Ab |
New compounds
|
|
US7244745B2
(en)
|
2002-08-30 |
2007-07-17 |
Memory Pharmaceuticals Corp. |
Heterocyclic compounds, methods for the preparation thereof, and uses thereof
|
|
CN100484937C
(zh)
|
2002-09-25 |
2009-05-06 |
记忆药物公司 |
吲唑、苯并噻唑和苯并异噻唑，以及它们的制备和用途
|
|
EP1562959A2
(en)
|
2002-11-01 |
2005-08-17 |
Pharmacia & Upjohn Company LLC |
Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
|
|
WO2004039366A1
(en)
|
2002-11-01 |
2004-05-13 |
Pharmacia & Upjohn Company Llc |
Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
|
|
EP1949901B1
(en)
|
2002-12-06 |
2014-02-12 |
The Feinstein Institute for Medical Research |
A method for determining a cholinergic agonist selective for an alpha 7 nicotinic receptor
|
|
EA200500783A1
(ru)
|
2002-12-11 |
2005-12-29 |
ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи |
Комбинация для лечения синдрома дефицита внимания с гиперактивностью
|
|
MXPA05005666A
(es)
|
2002-12-11 |
2005-07-26 |
Pharmacia & Upjohn Co Llc |
Tratamiento de enfermedades con combinaciones de agonistas del receptor nicotinico de acetilcolina alfa-7 y otros compuestos.
|
|
US6917746B2
(en)
|
2002-12-17 |
2005-07-12 |
3M Innovative Properties Company |
Apparatus and method for creating a fiber optic circuit
|
|
US6777617B2
(en)
|
2002-12-30 |
2004-08-17 |
3M Innovative Properties Company |
Telecommunications terminal
|
|
DE602004023586D1
(de)
|
2003-02-27 |
2009-11-26 |
Neurosearch As |
Neue diazabicyclische arylderivate
|
|
WO2005005435A1
(en)
|
2003-07-08 |
2005-01-20 |
Astrazeneca Ab |
Spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor
|
|
WO2005030778A1
(en)
|
2003-09-25 |
2005-04-07 |
Astrazeneca Ab |
Ligands
|
|
WO2005042538A1
(en)
|
2003-10-21 |
2005-05-12 |
Astrazeneca Ab |
Spirofuropyridine aryl derivatives
|
|
US7160876B2
(en)
|
2003-12-22 |
2007-01-09 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US20050137217A1
(en)
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
Spirocyclic quinuclidinic ether derivatives
|
|
US20050137398A1
(en)
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
3-Quinuclidinyl heteroatom bridged biaryl derivatives
|
|
US20050137203A1
(en)
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
3-quinuclidinyl amino-substituted biaryl derivatives
|
|
US20050245531A1
(en)
|
2003-12-22 |
2005-11-03 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
|
US20080227772A1
(en)
*
|
2004-02-04 |
2008-09-18 |
Neurosearch A/S |
Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands
|
|
US7488737B2
(en)
|
2004-04-22 |
2009-02-10 |
Memory Pharmaceutical Corporation |
Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
|
|
AU2005243147A1
(en)
|
2004-05-07 |
2005-11-24 |
Memory Pharmaceuticals Corporation |
1H-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
|
|
AU2005298693A1
(en)
*
|
2004-10-20 |
2006-05-04 |
Neurosearch A/S |
Novel diazabicyclic aryl derivatives and their medical use
|
|
WO2006065209A1
(en)
|
2004-12-15 |
2006-06-22 |
Astrazeneca Ab |
Nicotinic acetylcholine receptor ligands
|
|
BRPI0517494A
(pt)
*
|
2004-12-22 |
2008-10-14 |
Memory Pharm Corp |
composto, composição farmacêutica, método de ativação/estimulação seletiva de receptores nicotìnicos de a-7 em um paciente em que tal ativação/estimulação tem um efeito terapêutico, método de tratamento de um paciente que sofre de uma doença psicótica, uma doença neurodegenerativa que envolve uma disfunção do sistema colinérgico, e/ou uma condição de debilitação da memória e/ou da cognição, método de tratamento de um paciente que sofre de demência e/ou uma outra condição com perda da memória, método de tratamento de um paciente que sofre de debilitação da memória devido à debilitação cognitiva suave devido ao envelhecimento, mal de alzheimer, esquizofrenia, mal de parkinson, mal de huntington, mal de pick, mal de creutzfeldt-jakob, depressão, envelhecimento, trauma na cabeça, acidente vascular cerebral, hipoxia do snc, senilidade cerebral, demência de multiinfarto, hiv e/ou doença cardiovascular, método de tratamento e/ou prevenção da demência em um paciente com o mal de alzheimer, método de tratamento de um paciente para cortar o vìcio do álcool ou o tratamento de um paciente com a terapia anti-intoxicação, método de tratamento de um paciente para propiciar neuroproteção contra os danos associados com acidentes vasculares cerebrais e isquemia e excitotoxicidade induzida por glutamatos, método de tratamento de um paciente que sofre do vìcio da nicotina, dor, tontura do fuso horário, obesidade e/ou diabetes, método de indução do ato de parar fumar em um paciente, método de tratamento de um paciente que sofre de debilitação cognitiva suave (mci), demência vascular (vad), declìnio cognitivo associado com a idade (aacd), amnésia associada com a cirurgia com o coração aberto, parada cardìaca, anestesia geral, deficiências da memória devido à exposição a agentes anestésicos, debilitação cognitiva induzida pela privação do sono, sìndrome de fadiga crÈnica, narcolepsia, demência relacionada com a aids, debilitação cognitiva relacionada com a epilepsia, sìndrome de down, demência relacionada ao alcoolismo, debilitações da memória induzidas por drogas/substáncias, demência pugilìstica (sìndrome do boxeador), ou demência animal, método para o tratamento da perda da memória, método para o tratamento de um paciente que sofre de debilitação da memória, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da disfunção da transmissão do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante de receptores nicotìnicos de acetilcolina defeituosos ou funcionando mal em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da transmissão suprimida do receptor nicotìnico de acetilcolina em um paciente, método para o tratamento ou a profilaxia de uma doença ou de uma condição resultante da perda de sinapses colinérgicas em um paciente, método para a proteção dos neurÈnios em um paciente com neurotoxicidade induzi
|
|
US8093269B2
(en)
|
2005-06-07 |
2012-01-10 |
University Of Florida Research Foundation |
Alpha 7 nicotinic receptor selective ligands
|
|
DE602006017235D1
(de)
|
2005-08-22 |
2010-11-11 |
Targacept Inc |
Heteroarylsubstituierte diazatricycloalkane, verfahren zu deren herstellung und deren anwendung
|
|
AU2006295397A1
(en)
|
2005-09-23 |
2007-04-05 |
Memory Pharmaceuticals Corporation |
Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
|
|
US8316104B2
(en)
*
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
|
SA08290475B1
(ar)
*
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
AU2009214625A1
(en)
*
|
2008-02-13 |
2009-08-20 |
Targacept, Inc. |
Combination of alpha 7 nicotinic agonists and antipsychotics
|